Marcie Glicksman, Ph.D. is the scientific director at ORIG3N. ORIG3N combines genetics and regenerative medicine by leading the development of allogeneic derived cell therapies, iPSC (Induced Pluripotent Stem Cells) by leveraging the world's largest uniformly consented HLA-compliant cell bank. ORIG3N also offers a wide range of direct-to-consumer DNA tests that help people learn more about their genes and the role they play in health and wellness. Dr. Glicksman has a BA from Brown University and a Ph.D. in Neuroscience from the University of Washington. Dr. Glicksman has more than 75 publications and 12 issued patents. Dr. Glicksman has been in the field of drug discovery for more than 20 years. She worked in the biopharmaceutical industry for 13 years and then was on the faculty for ten years at Harvard Medical School and Brigham and Women's Hospital and co-directed the Laboratory for Neurodegenerative Drug Discovery (LDDN). In her career, she has run multiple advanced therapeutic programs, including clinic-tested drug candidates. She serves on the scientific advisory boards of the Alzheimer Drug Discovery Foundation (ADDF) and the California Institute for Regenerative Medicine (CIRM), and reviews grants for the NIH, the Department of Defense, the Michael J Fox Foundation, the Association Alzheimer's and the Rett Foundation
